Jazz Pharmaceuticals PLC (JAZZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Jazz Pharmaceuticals PLC (JAZZ) Financials: Revenue, Profit and Cash Flow
Jazz Pharmaceuticals reported revenue of $4.27B for the fiscal year ended Dec 31, 2025, up 4.9% from the year before. That year, net income was -$356.15M with a net margin of -8.3%, operating cash flow was $1.36B and free cash flow was $438.97M. The quarter ended Sep 30, 2026 had revenue of $1.24B and net income of -$483.40M.
Revenue and Margins
The operating margin was -10.1% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.49B, a compound annual rate of 12.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.27B | +4.9% | 88.2% | -10.1% | -8.3% |
| Dec 2024 | $4.07B | +6.1% | 89.0% | 17.6% | 13.8% |
| Dec 2023 | $3.83B | +4.8% | 88.6% | 15.1% | 10.8% |
| Dec 2022 | $3.66B | +18.3% | 85.2% | -1.8% | -6.1% |
| Dec 2021 | $3.09B | +30.9% | 85.8% | 5.5% | -10.7% |
| Dec 2020 | $2.36B | +9.3% | 93.7% | 16.0% | 10.1% |
| Dec 2019 | $2.16B | +14.3% | 94.1% | 24.6% | 24.2% |
| Dec 2018 | $1.89B | +16.8% | 93.6% | 32.5% | 23.6% |
| Dec 2017 | $1.62B | +8.8% | 93.2% | 32.7% | 30.1% |
| Dec 2016 | $1.49B | N/A | 92.9% | 39.8% | 26.7% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B |
| Cost of revenue | $503.30M | $445.71M | $435.58M | $540.52M | $440.76M | $148.92M | $127.93M | $121.54M | $110.19M | $105.39M |
| Gross profit | $3.76B | $3.62B | $3.40B | $3.12B | $2.65B | $2.21B | $2.03B | $1.77B | $1.51B | $1.38B |
| Research and development | $1.73B | $894.00M | $868.66M | $1.03B | $505.75M | $586.63M | $409.70M | $226.62M | $283.44M | $186.05M |
| Operating income | -$430.24M | $716.63M | $578.58M | -$65.53M | $170.28M | $378.07M | $532.37M | $614.84M | $528.84M | $591.65M |
| Net income | -$356.15M | $560.12M | $414.83M | -$224.06M | -$329.67M | $238.62M | $523.37M | $447.10M | $487.85M | $396.83M |
| EBITDA | $263.49M | $1.37B | $1.23B | $544.93M | $718.41M | $653.05M | $896.72M | $868.65M | $714.05M | $730.94M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.24B | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $897.80M | $1.09B | $1.05B | $1.02B | $901.98M | $1.01B |
| Gross profit | $1.13B | $1.09B | $934.80M | $1.04B | $997.20M | $929.40M | $793.20M | $959.46M | $943.36M | $913.92M | $806.50M | $904.69M |
| Operating income | -$413.40M | $248.20M | $336.60M | $254.53M | $57.50M | -$686.40M | -$55.90M | $190.77M | $260.21M | $199.44M | $66.21M | $122.50M |
| Net income | -$483.40M | $192.80M | $293.10M | $203.45M | $251.40M | -$718.50M | -$92.50M | $191.12M | $215.06M | $168.57M | -$14.62M | $94.15M |
Balance Sheet
As of Dec 2025, total debt of $5.36B exceeded cash and equivalents by $3.97B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B |
| Current assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968.28M | $748.07M |
| Cash and equivalents | $1.39B | $2.41B | $1.51B | $881.48M | $591.45M | $1.06B | $637.34M | $309.62M | $386.04M | $365.96M |
| Total liabilities | $7.34B | $7.92B | $7.66B | $7.75B | $8.33B | $2.88B | $2.43B | $2.45B | $2.41B | $2.92B |
| Short-term debt | $1.03B | $31.00M | $604.95M | $31.00M | $31.00M | $246.32M | $33.39M | $33.39M | $40.60M | $36.09M |
| Long-term debt | $4.33B | $6.08B | $5.11B | $5.69B | $6.02B | $1.85B | $1.57B | $1.56B | $1.54B | $1.99B |
| Shareholder equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.00B | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | $11.39B |
| Total liabilities | $7.81B | $6.28B | $7.33B | $7.34B | $7.40B | $7.24B | $7.36B | $7.92B | $8.08B | $7.60B | $7.63B | $7.66B |
| Cash and equivalents | $2.04B | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | $1.21B |
| Shareholder equity | $4.19B | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 32.3% of operating cash flow. Share repurchases came to 28.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.51M | $899.65M | $776.40M | $798.90M | $693.09M | $592.39M |
| Capital expenditures | $916.80M | $38.07M | $23.96M | $29.05M | $27.64M | $15.00M | $40.13M | $20.37M | $28.95M | $9.69M |
| Free cash flow | $438.97M | $1.36B | $1.07B | $1.24B | $750.87M | $884.64M | $736.27M | $778.53M | $664.14M | $582.70M |
| Dividends paid | N/A | N/A | N/A | $98.02M | $99.66M | $99.68M | $57.83M | N/A | $0 | $0 |
| Share repurchases | $125.02M | $311.43M | $269.76M | $54.00K | $0 | $146.54M | $301.45M | $523.67M | $98.80M | $278.30M |
| Investing cash flow | -$1.51B | -$508.19M | -$163.06M | -$446.23M | -$5.21B | -$1.01B | -$155.30M | -$394.49M | -$268.95M | -$1.75B |
| Financing cash flow | -$873.38M | $20.52M | -$305.25M | -$529.49M | $3.97B | $528.07M | -$293.75M | -$479.13M | -$409.11M | $540.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $506.10M | $415.70M | $408.20M | $362.52M | $474.70M | $88.80M | $429.80M | $398.58M | $398.75M | $331.35M | $267.23M | $167.34M |
| Capital expenditures | $847.00M | $18.10M | $96.90M | $16.73M | $15.20M | $871.00M | $13.90M | $13.29M | $10.79M | $7.09M | $6.90M | $10.10M |
| Free cash flow | -$340.90M | $397.60M | $311.30M | $345.79M | $459.50M | -$782.20M | $415.90M | $385.29M | $387.96M | $324.26M | $260.32M | $157.24M |
Frequently Asked Questions About JAZZ
What is Jazz Pharmaceuticals' annual revenue?
Jazz Pharmaceuticals reported revenue of $4.27B for the fiscal year ended Dec 31, 2025.
How fast is Jazz Pharmaceuticals' revenue growing?
Revenue was up 4.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.3%.
Is Jazz Pharmaceuticals profitable?
No. Jazz Pharmaceuticals reported net income of -$356.15M for the fiscal year ended Dec 31, 2025, with a net margin of -8.3%.
How much free cash flow does JAZZ generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.36B minus capital expenditures of $916.80M produced free cash flow of $438.97M.
How much debt does Jazz Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $4.33B, short-term debt of $1.03B and cash and equivalents of $1.39B.
JAZZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts